Physician profile
Donna Mendonca
NPI 1710413786
$1,441.52
in general payments reported to CMS, 2019-2025
11 companies · $686 in 2025
The $686 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $137 · 2023: $236 · 2024: $199 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,121.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $407.25 | 2022-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $393.18 | 2021-2025 | Wegovy |
| Abbott Laboratories | $125.00 | 2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $119.79 | 2025 | Farxiga |
| Advanced Oxygen Therapy INC. | $111.48 | 2023 | Topical Oxygen Chamber For Extremities |
| Bayer Healthcare Pharmaceuticals INC. | $89.99 | 2022 | |
| Janssen Pharmaceuticals, INC | $57.17 | 2024 | Xarelto |
| Dexcom, INC. | $52.27 | 2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $43.82 | 2021 | |
| Alnylam Pharmaceuticals INC. | $27.04 | 2022 | |
| Merck Sharp & Dohme LLC | $14.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Mendonca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.